See the DrugPatentWatch profile for Lemtrada
What is Lemtrada and who makes it?
Lemtrada, also known as alemtuzumab, is a medication used to treat multiple sclerosis (MS), a chronic autoimmune disease. It is administered via a one-year-course of treatment with a short two-week lead-in phase followed by a 12-week on-treatment phase and a 12-week off-treatment phase.
Who makes Lemtrada?
Lemtrada was initially developed by Genzyme, a biotechnology company, and later purchased by Sanofi, a French multinational pharmaceutical company, in 2011. [1]
How does Lemtrada work?
Lemtrada targets the immune system by depleting lymphocytes, a type of white blood cell that can contribute to the progression of MS. This depletion reduces the number of cells that can penetrate the protective lining of the central nervous system, reducing inflammation and damage.
What are the benefits and risks of Lemtrada?
In clinical trials, Lemtrada was shown to significantly reduce disease activity and disability in patients with MS. However, like all medications, it carries risks, including infusion-related reactions, autoimmune disorders, and thyroid problems. It's essential to weigh the benefits and risks with a healthcare professional before starting treatment.
What are the differences between Lemtrada and other MS treatments?
Lemtrada differs from other MS treatments in its mechanism of action and administration route. It's a monoclonal antibody that targets a specific protein on lymphocytes, unlike other treatments that target various immune cells or pathways. Lemtrada's treatment duration is also distinct, requiring a one-year course of intravenous infusions.
What are the side effects of Lemtrada that patients ask about?
Common side effects of Lemtrada include infusion-related reactions, thyroid problems, infections, and changes in blood cell counts. Some patients have reported autoimmune disorders, such as thyroid disease, rheumatoid arthritis, and lupus-like conditions. It's crucial for patients to discuss potential side effects with their healthcare provider before treatment.
When does exclusivity on Lemtrada expire?
The patent for Lemtrada is set to expire in certain countries, including the United States, in the mid-2030s. However, Sanofi may have granted licenses or has other protection under law that could extend exclusivity on the medication.
Can biosimilars enter the market before Lemtrada's patent expires?
Sanofi has been facing challenges from generic manufacturers attempting to enter the Lemtrada market. However, the FDA has not approved any biosimilars for Lemtrada, and any future approvals would need to demonstrate similarity in safety, efficacy, and quality.
References
[1] Sanofi. (n.d.). Lemtrada (Alemtuzumab). Retrieved from https://www.sanofi.com/en/diseases-treatments/our-disease-guides/Multiple-Sclerosis [2] DrugPatentWatch.com. (n.d.). Lemtrada (Alemtuzumab). Retrieved from https://www.drugpatentwatch.com/Drug/LEMT
Source:
[1] Sanofi
[2] DrugPatentWatch.com